Skip to main content

Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
famotidine
proton pump inhibitors
single-agent H2 receptor antagonists
Description

In this report, we identified new and prevalent users of proton pump inhibitors (PPIs), single-agent H2 receptor antagonists (H2RAs), and famotidine who had a diagnosis of gastroesophageal reflux disease (GERD) in the Rapid Sentinel Distributed Database (SDD). We also estimated the incidence of COVID-19 and COVID-19-related adverse outcomes among these individuals.

The study period includes data from April 1, 2020 to December 15, 2020. We distributed this request to seven Sentinel Data Partners (DPs) on June 3, 2022.

Deliverables (1)
Sentinel Modular Program Report: Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
April 1, 2020 - December 15, 2020
Analysis Type
Descriptive
Population / Cohort
Individuals 18 years of age and older
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Proton Pump Inhibitors & COVID-19 Hospitalization and Severe COVID-19